[go: up one dir, main page]

BR9906903A - Composição com liberação sustentada, processos para produzir a mesma, para suprimir a brusca liberação inicial da susbtância bioativa de uma composição com liberação sustentada e para aumentar a eficiência da inclusão da substância bioativa em uma composição com liberação sustentada, produto farmacêutico, agente para prevenir ou tratar câncer prostático, hipertrofia prostática, endometriose, histeromioma, metrofibroma, puberdade precoce, dismenorréia, ou câncer do seio, ou um contraceptivo, e, composto - Google Patents

Composição com liberação sustentada, processos para produzir a mesma, para suprimir a brusca liberação inicial da susbtância bioativa de uma composição com liberação sustentada e para aumentar a eficiência da inclusão da substância bioativa em uma composição com liberação sustentada, produto farmacêutico, agente para prevenir ou tratar câncer prostático, hipertrofia prostática, endometriose, histeromioma, metrofibroma, puberdade precoce, dismenorréia, ou câncer do seio, ou um contraceptivo, e, composto

Info

Publication number
BR9906903A
BR9906903A BR9906903-2A BR9906903A BR9906903A BR 9906903 A BR9906903 A BR 9906903A BR 9906903 A BR9906903 A BR 9906903A BR 9906903 A BR9906903 A BR 9906903A
Authority
BR
Brazil
Prior art keywords
composition
sustained release
bioactive substance
release
metrofibroma
Prior art date
Application number
BR9906903-2A
Other languages
English (en)
Inventor
Akira Saikawa
Yasutaka Igari
Yoshio Hata
Kazumichio Yamamoto
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of BR9906903A publication Critical patent/BR9906903A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

"COMPOSIçãO COM LIBERAçãO SUSTENTADA, PROCESSOS PARA PRODUZIR A MESMA, PARA SUPRIMIR A BRUSCA LIBERAçãO INICIAL DA SUBSTâNCIA BIOATIVA DE UMA COMPOSIçãO COM LIBERAçãO SUSTENTADA E PARA AUMENTAR EFICIêNCIA DA INCLUSãO DA SUBSTâNCIA BIOATIVA EM UMA COMPOSIçãO COM LIBERAçãO SUSTENTADA, PRODUTO FARMACêUTICO, AGENTE PARA PREVENIR OU TRATAR CâNCER PROSTáTICO, HIPERTROFIA PROSTáTICA, ENDOMETRIOSE, HISTEROMIOMA, METROFIBROMA, PUBERDADE PRECOCE, DISMENORRéIA, OU CâNCER DO SEIO, OU UM CONTRACEPTIVO, E, COMPOSTO" Composição com liberação sustentada contendo um sal de ácido hidroxinaftóico de uma substância biologicamente ativa e um polímero biodegradável, uma processo para sua produção, e uma composição farmacêutica contendo a mencionada composição com liberação sustentada.
BR9906903-2A 1998-01-16 1999-01-13 Composição com liberação sustentada, processos para produzir a mesma, para suprimir a brusca liberação inicial da susbtância bioativa de uma composição com liberação sustentada e para aumentar a eficiência da inclusão da substância bioativa em uma composição com liberação sustentada, produto farmacêutico, agente para prevenir ou tratar câncer prostático, hipertrofia prostática, endometriose, histeromioma, metrofibroma, puberdade precoce, dismenorréia, ou câncer do seio, ou um contraceptivo, e, composto BR9906903A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP641298 1998-01-16
PCT/JP1999/000086 WO1999036099A1 (fr) 1998-01-16 1999-01-13 Compositions a liberation controlee, leur procede de fabrication et leur utilisation

Publications (1)

Publication Number Publication Date
BR9906903A true BR9906903A (pt) 2000-12-12

Family

ID=11637664

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9906903-2A BR9906903A (pt) 1998-01-16 1999-01-13 Composição com liberação sustentada, processos para produzir a mesma, para suprimir a brusca liberação inicial da susbtância bioativa de uma composição com liberação sustentada e para aumentar a eficiência da inclusão da substância bioativa em uma composição com liberação sustentada, produto farmacêutico, agente para prevenir ou tratar câncer prostático, hipertrofia prostática, endometriose, histeromioma, metrofibroma, puberdade precoce, dismenorréia, ou câncer do seio, ou um contraceptivo, e, composto

Country Status (19)

Country Link
US (2) US6740634B1 (pt)
EP (1) EP1048301A4 (pt)
KR (1) KR100577877B1 (pt)
CN (1) CN1199686C (pt)
AU (1) AU758596B2 (pt)
BR (1) BR9906903A (pt)
CA (1) CA2316273A1 (pt)
HR (1) HRP20000471A2 (pt)
HU (1) HUP0100221A3 (pt)
IL (1) IL136951A0 (pt)
IS (1) IS5560A (pt)
NO (1) NO20003530L (pt)
NZ (1) NZ505651A (pt)
OA (1) OA11446A (pt)
PL (1) PL341733A1 (pt)
RU (1) RU2230550C2 (pt)
SK (1) SK10272000A3 (pt)
TR (1) TR200002059T2 (pt)
WO (1) WO1999036099A1 (pt)

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
PT1158014E (pt) * 1998-12-15 2005-04-29 Takeda Pharmaceutical Processo para a producao de poliesteres biodegradaveis
CZ2002114A3 (cs) * 1999-07-15 2002-04-17 Takeda Chemical Industries, Ltd. Prostředek s trvalým uvolňováním, způsob jeho výroby a jeho pouľití
EP1297850B1 (en) 2000-07-05 2015-08-19 Takeda Pharmaceutical Company Limited Medicinal preparations for treating sex hormone-dependent diseases
KR100772950B1 (ko) * 2000-08-07 2007-11-02 와꼬 쥰야꾸 고교 가부시키가이샤 젖산 중합체 및 이의 제조 방법
DE10040700A1 (de) 2000-08-17 2002-02-28 Asta Medica Ag Salze von biologisch aktiven Peptiden, ihre Herstellung und Verwendung
WO2002043766A1 (fr) * 2000-11-29 2002-06-06 Takeda Chemical Industries, Ltd. Compositions medicinales et leur procede de preparation
WO2002047722A1 (fr) * 2000-12-15 2002-06-20 Takeda Chemical Industries, Ltd. Compositions medicinales agoniste ou antagoniste de la gonadoliberine non peptidyl, methode de production et utilisation desdites compositions
EP1374855A1 (en) * 2001-03-30 2004-01-02 Takeda Chemical Industries, Ltd. Medicinal solutions
CA2444727A1 (en) * 2001-04-25 2002-11-07 Takeda Chemical Industries, Ltd. Agents for preventing postoperative recurrence of premenopausal breast cancer
US7344507B2 (en) 2002-04-19 2008-03-18 Pelikan Technologies, Inc. Method and apparatus for lancet actuation
TW200526267A (en) * 2001-06-29 2005-08-16 Takeda Chemical Industries Ltd Controlled release composition and method of producing the same
TWI225416B (en) * 2001-06-29 2004-12-21 Takeda Chemical Industries Ltd Sustained-release composition and process for producing the same
ATE498408T1 (de) * 2001-08-10 2011-03-15 Takeda Pharmaceutical Gnrh-agonistische kombinationsmittel
JP2005509611A (ja) 2001-10-10 2005-04-14 ピエール、ファーブル、メディカマン 徐放型生物分解性微小球およびその製造方法
WO2003041739A1 (en) 2001-11-13 2003-05-22 Takeda Chemical Industries, Ltd. Anticaner agents
CN101444476B (zh) * 2001-12-26 2011-11-30 武田药品工业株式会社 新微球和其生产方法
US7674232B2 (en) 2002-04-19 2010-03-09 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
KR101041767B1 (ko) * 2002-06-25 2011-06-17 다케다 야쿠힌 고교 가부시키가이샤 서방성 조성물의 제조 방법
AU2003266581A1 (en) * 2002-09-24 2004-04-19 Asahi Kasei Chemicals Corporation Glycolic acid copolymer and method for production thereof
US20070207211A1 (en) * 2003-04-10 2007-09-06 Pr Pharmaceuticals, Inc. Emulsion-based microparticles and methods for the production thereof
WO2005003180A2 (en) 2003-04-10 2005-01-13 Pr Pharmaceuticals A method for the production of emulsion-based micro particles
ES2625343T3 (es) * 2003-07-15 2017-07-19 Evonik Corporation Método para la preparación de formulaciones de liberación controlada
JP5165240B2 (ja) 2003-07-23 2013-03-21 ピーアール ファーマシューティカルズ， インコーポレイテッド 徐放組成物
US20070276024A1 (en) * 2003-10-09 2007-11-29 Inverseon , Inc. Methods for Treating Diseases and Conditions with Inverse Agonists and for Screening for Agents Acting as Inverse Agonists
CA2544611A1 (en) * 2003-10-09 2005-04-21 Inverseon, Inc. Method of treating airway diseases with beta-adrenergic inverse agonists
TW200529890A (en) * 2004-02-10 2005-09-16 Takeda Pharmaceutical Sustained-release preparations
TW200613012A (en) * 2004-07-02 2006-05-01 Takeda Pharmaceuticals Co Sustained-release composition, process for producing the same and use of the same
US7528175B2 (en) * 2004-10-08 2009-05-05 Inverseon, Inc. Method of treating airway diseases with beta-adrenergic inverse agonists
US20060222716A1 (en) * 2005-04-01 2006-10-05 Joseph Schwarz Colloidal solid lipid vehicle for pharmaceutical use
US20090156545A1 (en) * 2005-04-01 2009-06-18 Hostetler Karl Y Substituted Phosphate Esters of Nucleoside Phosphonates
EP1866319B1 (en) 2005-04-01 2011-11-23 The Regents of The University of California Phosphono-pent-2-en-1-yl nucleosides and analogs
DE602006000381T2 (de) 2005-04-28 2008-12-18 Nipro Corp., Osaka Bioabsorbierbare pharmazeutische Zusammensetzung enthaltend einen PLGA-Copolymer
US20070027107A1 (en) * 2005-07-29 2007-02-01 Curt Hendrix Compositions and methods for treating estrogen-dependent diseases and conditions
EP3363455A1 (en) 2005-12-30 2018-08-22 Zensun (Shanghai) Science & Technology, Co., Ltd. Extended release of neuregulin for improved cardiac function
US20070232671A1 (en) * 2006-03-13 2007-10-04 Given Bruce D Methods and compositions for treatment of diastolic heart failure
DK2383271T3 (da) 2006-03-13 2013-10-07 Kyorin Seiyaku Kk Aminoquinoloner som GSK-3-inhibitorer
WO2007106468A2 (en) * 2006-03-13 2007-09-20 Encysive Pharmaceuticals, Inc. Formulations of sitaxsentan sodium
US20080026061A1 (en) * 2006-06-22 2008-01-31 Reichwein John F Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide
KR20090068263A (ko) 2006-09-21 2009-06-25 액티브스 바이오사이언시즈, 인크. 세린 가수분해효소 억제제
WO2008057604A2 (en) * 2006-11-08 2008-05-15 The Regents Of The University Of California Small molecule therapeutics, syntheses of analogues and derivatives and methods of use
NZ577281A (en) * 2006-12-18 2011-12-22 Takeda Pharmaceutical Sustained-release composition and method for producing the same
US7892776B2 (en) 2007-05-04 2011-02-22 The Regents Of The University Of California Screening assay to identify modulators of protein kinase A
RU2343908C1 (ru) * 2007-09-05 2009-01-20 Руслан Дмитриевич Илюк Средство для профилактики и лечения алкоголизма и способ его применения
KR101563018B1 (ko) * 2007-09-11 2015-10-23 교린 세이야꾸 가부시키 가이샤 Ｇｓｋ-３ 억제제로서의 시아노아미노퀴놀론 및 테트라졸로아미노퀴놀론
CN102344457B (zh) 2007-09-12 2015-07-22 杏林制药株式会社 作为 gsk-3 抑制剂的螺环状氨基喹诺酮
WO2009139880A1 (en) * 2008-05-13 2009-11-19 Celgene Corporation Thioxoisoindoline compounds and compositions and methods of using the same
ES2456275T3 (es) 2009-02-27 2014-04-21 Ambit Biosciences Corporation Derivados de quinazolina moduladores de la quinasa JAK y su uso en métodos
KR101748891B1 (ko) 2009-03-11 2017-06-19 교린 세이야꾸 가부시키 가이샤 Ｇｓｋ-3 억제제로서의 7-시클로알킬아미노퀴놀론
KR20120059558A (ko) 2009-08-19 2012-06-08 암비트 바이오사이언시즈 코포레이션 바이아릴 화합물 및 이의 사용 방법
US20110301235A1 (en) 2009-12-02 2011-12-08 Alquest Therapeutics, Inc. Organoselenium compounds and uses thereof
WO2011079313A1 (en) * 2009-12-23 2011-06-30 Map Pharmaceuticals, Inc. Novel ergoline analogs
WO2011150201A2 (en) 2010-05-27 2011-12-01 Ambit Biosciences Corporation Azolyl amide compounds and methods of use thereof
WO2011150198A1 (en) 2010-05-27 2011-12-01 Ambit Biosciences Corporation Azolyl urea compounds and methods of use thereof
AU2011296024B2 (en) 2010-09-01 2015-05-28 Ambit Biosciences Corporation Quinazoline compounds and methods of use thereof
WO2012082521A2 (en) * 2010-12-15 2012-06-21 3M Innovative Properties Company Degradable fibers
WO2012096866A2 (en) 2011-01-10 2012-07-19 Inverseon, Inc. Use of beta-adrenergic inverse agonists for smoking cessation
AR082266A1 (es) * 2011-05-13 2012-11-28 Univ Nac Del Litoral Microparticula inyectable de liberacion controlada
WO2012177962A1 (en) 2011-06-23 2012-12-27 Map Pharmaceuticals, Inc. Novel fluoroergoline analogs
BR112014009006B8 (pt) 2011-10-14 2022-05-31 Ambit Biosciences Corp Compostos heterocíclicos e métodos de uso dos mesmos
WO2013095707A1 (en) 2011-12-19 2013-06-27 Map Pharmaceuticals, Inc. Novel iso-ergoline derivatives
WO2013095708A1 (en) 2011-12-21 2013-06-27 Map Pharmaceuticals, Inc. Novel neuromodulatory compounds
US9012640B2 (en) 2012-06-22 2015-04-21 Map Pharmaceuticals, Inc. Cabergoline derivatives
WO2014100354A1 (en) 2012-12-21 2014-06-26 Map Pharmaceuticals, Inc. Novel methysergide derivatives
SG11201601341QA (en) 2013-08-30 2016-03-30 Ambit Biosciences Corp Biaryl acetamide compounds and methods of use thereof
US9499514B2 (en) 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
TW201618783A (zh) 2014-08-07 2016-06-01 艾森塔製藥公司 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法
EP3777863A1 (en) 2014-09-12 2021-02-17 Tobira Therapeutics, Inc. Cenicriviroc combination therapy for the treatment of fibrosis
EP3209658A1 (en) 2014-10-24 2017-08-30 Biogen MA Inc. Diterpenoid derivatives and methods of use thereof
CA2974113A1 (en) 2015-01-20 2016-07-28 Xoc Pharmaceuticals, Inc. Isoergoline compounds and uses thereof
US9657020B2 (en) 2015-01-20 2017-05-23 Xoc Pharmaceuticals, Inc. Ergoline compounds and uses thereof
SI3640345T1 (sl) 2015-08-17 2022-01-31 Kura Oncology, Inc. Postopki za zdravljenje rakavih pacientov z inhibitorji farneziltransferaze
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
AU2016365400C1 (en) 2015-12-02 2022-11-10 Astraea Therapeutics, Llc Piperidinyl nociceptin receptor compounds
SG11201805779TA (en) 2016-01-08 2018-08-30 Celgene Corp Antiproliferative compounds, and their pharmaceutical compositions and uses
CA3010794A1 (en) 2016-01-08 2017-07-13 Celgene Corporation Solid forms of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses
WO2017180794A1 (en) 2016-04-13 2017-10-19 Skyline Antiinfectives, Inc. Deuterated o-sulfated beta-lactam hydroxamic acids and deuterated n-sulfated beta-lactams
WO2017184968A1 (en) 2016-04-22 2017-10-26 Kura Oncology, Inc. Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
EP3534885B1 (en) 2016-11-03 2021-01-20 Kura Oncology, Inc. Farnesyltransferase inhibitors for use in treating cancer
US10106521B2 (en) 2016-11-09 2018-10-23 Phloronol, Inc. Eckol derivatives, methods of synthesis and uses thereof
MX2019009821A (es) 2017-02-21 2019-12-02 Kura Oncology Inc Metodos para tratar cancer con inhibidores de farnesiltransferasa.
US10137121B2 (en) 2017-02-21 2018-11-27 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
CN111132980A (zh) 2017-06-01 2020-05-08 Xoc制药股份有限公司 用于医学的麦角灵衍生物
US10806730B2 (en) 2017-08-07 2020-10-20 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
SG11202000894TA (en) 2017-08-07 2020-02-27 Kura Oncology Inc Methods of treating cancer with farnesyltransferase inhibitors
WO2019113269A1 (en) 2017-12-08 2019-06-13 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
TW202031259A (zh) 2018-11-01 2020-09-01 美商庫拉腫瘤技術股份有限公司 以法尼基轉移酶(farnesyltransferase)抑制劑治療癌症之方法
WO2020132071A1 (en) 2018-12-19 2020-06-25 Shy Therapeutics. Llc Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and f1brotic disease
CN113365630A (zh) 2018-12-21 2021-09-07 库拉肿瘤学公司 用于鳞状细胞癌的疗法
US11447468B2 (en) 2019-02-06 2022-09-20 Dice Alpha, Inc. IL-17 ligands and uses thereof
US20220142983A1 (en) 2019-03-01 2022-05-12 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
US20220143006A1 (en) 2019-03-15 2022-05-12 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
TW202043487A (zh) 2019-03-29 2020-12-01 美商庫拉腫瘤技術股份有限公司 以法尼基轉移酶(farnesyltransferase)抑制劑治療鱗狀細胞癌之方法
WO2020205387A1 (en) 2019-04-01 2020-10-08 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
US20220305001A1 (en) 2019-05-02 2022-09-29 Kura Oncology, Inc. Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
EP4031534A1 (en) 2019-09-16 2022-07-27 Dice Alpha, Inc. Il-17a modulators and uses thereof
US11529331B2 (en) 2020-05-29 2022-12-20 Boulder Bioscience Llc Methods for improved endovascular thrombectomy using 3,3′-diindolylmethane
US20230227466A1 (en) 2020-06-18 2023-07-20 Shy Therapeutics, Llc Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
US12024521B2 (en) 2020-06-30 2024-07-02 Prosetta Biosciences, Inc. Isoquinoline derivatives, methods of synthesis and uses thereof
WO2022164997A1 (en) 2021-01-27 2022-08-04 Shy Therapeutics, Llc Methods for the treatment of fibrotic disease
US20240309015A1 (en) 2021-01-27 2024-09-19 Shy Therapeutics, Llc Methods for the Treatment of Fibrotic Disease
US20240208968A1 (en) 2021-03-10 2024-06-27 Dice Molecules Sv, Inc. Alpha v beta 6 and alpha v beta 1 integrin inhibitors and uses thereof
EP4326721A1 (en) 2021-04-22 2024-02-28 Protego Biopharma, Inc. Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis
EP4347568A1 (en) 2021-05-27 2024-04-10 Protego Biopharma, Inc. Heteroaryl diamide ire1/xbp1s activators
EP4402124A1 (en) 2021-10-22 2024-07-24 Prosetta Biosciences, Inc. Novel host-targeted pan-respiratory antiviral small molecule therapeutics
KR102709458B1 (ko) * 2021-11-23 2024-09-23 한국화학연구원 서방출 클로니딘 미립구형 주사제 및 그의 제조방법
JP2024544059A (ja) 2021-11-30 2024-11-27 クラ オンコロジー， インコーポレイテッド ファルネシルトランスフェラーゼ阻害活性を有する大環状化合物
JP2025501308A (ja) 2022-01-03 2025-01-17 ライラック セラピューティクス， インク． 非環式チオールプロドラッグ
WO2023129577A1 (en) 2022-01-03 2023-07-06 Lilac Therapeutics, Inc. Cyclic thiol prodrugs
EP4484415A1 (en) * 2022-02-22 2025-01-01 Shanghai Yonsun Biotechnology Co., Ltd. Medicinal salt of cariprazine and crystal form thereof, pharmaceutical composition thereof, and preparation method therefor and use thereof
EP4463158A2 (en) 2022-03-02 2024-11-20 Mitopower, Inc. Novel prodrugs derived from nicotinic acid and ribose
EP4499828A1 (en) 2022-03-30 2025-02-05 BioMarin Pharmaceutical Inc. Dystrophin exon skipping oligonucleotides
GB2619907A (en) 2022-04-01 2023-12-27 Kanna Health Ltd Novel crystalline salt forms of mesembrine
KR20250003774A (ko) 2022-04-14 2025-01-07 브리스톨-마이어스 스큅 컴퍼니 신규 gspt1 화합물 및 신규 화합물의 사용 방법
EP4508246A1 (en) 2022-04-15 2025-02-19 Celgene Corporation Methods for predicting responsiveness of lymphoma to drug and methods for treating lymphoma
US20230416741A1 (en) 2022-05-05 2023-12-28 Biomarin Pharmaceutical Inc. Method of treating duchenne muscular dystrophy
US20240158370A1 (en) 2022-09-09 2024-05-16 Innovo Therapeutics, Inc. CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS
US12171745B2 (en) 2022-09-30 2024-12-24 Boulder Bioscience Llc Compositions and methods for treating non-hemorrhagic closed head injury
US20240174695A1 (en) 2022-10-26 2024-05-30 Protego Biopharma, Inc. Spirocycle Containing Bicyclic Heteroaryl Compounds
WO2024092043A1 (en) 2022-10-26 2024-05-02 Protego Biopharma, Inc. Spirocycle containing pyridine compounds
US20240174672A1 (en) 2022-10-26 2024-05-30 Protego Biopharma, Inc. Spirocycle Containing Pyridone Compounds
WO2024118810A1 (en) 2022-11-30 2024-06-06 Protego Biopharma, Inc. Cyclic pyrazole diamide ire1/xbp1s activators
WO2024118801A1 (en) 2022-11-30 2024-06-06 Protego Biopharma, Inc. Linear heteroaryl diamide ire1/xbp1s activators
WO2024226471A2 (en) 2023-04-24 2024-10-31 Biomarin Pharmaceutical Inc. Compositions and methods for treating stxbp1 disorders
WO2024233303A1 (en) 2023-05-05 2024-11-14 Biomarin Pharmaceutical Inc. Dystrophin exon skipping oligonucleotides

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4049640A (en) * 1975-12-12 1977-09-20 American Cyanamid Company Substituted bisnaphthylazo diphenyl ureido complement inhibitors
US4211769A (en) * 1977-08-24 1980-07-08 Takeda Chemical Industries, Ltd. Preparations for vaginal administration
US4272398A (en) * 1978-08-17 1981-06-09 The United States Of America As Represented By The Secretary Of Agriculture Microencapsulation process
US5270305A (en) * 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
JPH07115233B2 (ja) * 1990-08-10 1995-12-13 株式会社ヨシツカ精機 粉末成形プレス
US5869097A (en) * 1992-11-02 1999-02-09 Alza Corporation Method of therapy comprising an osmotic caplet
JPH08259460A (ja) * 1995-01-23 1996-10-08 Takeda Chem Ind Ltd 徐放性製剤の製造法
AU4459196A (en) 1995-01-23 1996-08-14 Takeda Chemical Industries Ltd. Sustained-release preparation and use
US5565188A (en) * 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
US6132768A (en) * 1995-07-05 2000-10-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors
US5840835A (en) * 1995-10-30 1998-11-24 Merck & Co., Inc. Inhibitors of peptide binding to MHC class II proteins
US5635765A (en) * 1996-02-26 1997-06-03 Cypress Semiconductor Corporation Multi-layer gate structure
DK0889722T3 (da) 1996-03-28 2003-02-10 Takeda Chemical Industries Ltd Præparat med forsinket frigivelse og fremstilling deraf
GB9611194D0 (en) * 1996-05-29 1996-07-31 Smithkline Beecham Plc Container
CA2242335A1 (en) * 1996-11-15 1998-05-22 Pathogenesis Corporation Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections
WO1998032423A1 (en) 1997-01-29 1998-07-30 Takeda Chemical Industries, Ltd. Sustained-release microspheres, their production and use
CZ2002114A3 (cs) * 1999-07-15 2002-04-17 Takeda Chemical Industries, Ltd. Prostředek s trvalým uvolňováním, způsob jeho výroby a jeho pouľití
TW200526267A (en) * 2001-06-29 2005-08-16 Takeda Chemical Industries Ltd Controlled release composition and method of producing the same

Also Published As

Publication number Publication date
HUP0100221A3 (en) 2002-11-28
NZ505651A (en) 2003-08-29
IS5560A (is) 2000-07-11
NO20003530D0 (no) 2000-07-07
HUP0100221A2 (hu) 2001-06-28
KR100577877B1 (ko) 2006-05-09
OA11446A (en) 2004-04-30
IL136951A0 (en) 2001-06-14
AU758596B2 (en) 2003-03-27
PL341733A1 (en) 2001-05-07
SK10272000A3 (sk) 2001-01-18
RU2230550C2 (ru) 2004-06-20
US6740634B1 (en) 2004-05-25
CN1199686C (zh) 2005-05-04
CA2316273A1 (en) 1999-07-22
NO20003530L (no) 2000-09-14
WO1999036099A8 (fr) 1999-11-18
US20050025826A1 (en) 2005-02-03
EP1048301A4 (en) 2005-03-09
WO1999036099A1 (fr) 1999-07-22
EP1048301A1 (en) 2000-11-02
CN1288387A (zh) 2001-03-21
TR200002059T2 (tr) 2001-01-22
HRP20000471A2 (en) 2000-12-31
US7388032B2 (en) 2008-06-17
AU1889799A (en) 1999-08-02
KR20010033949A (ko) 2001-04-25

Similar Documents

Publication Publication Date Title
BR9906903A (pt) Composição com liberação sustentada, processos para produzir a mesma, para suprimir a brusca liberação inicial da susbtância bioativa de uma composição com liberação sustentada e para aumentar a eficiência da inclusão da substância bioativa em uma composição com liberação sustentada, produto farmacêutico, agente para prevenir ou tratar câncer prostático, hipertrofia prostática, endometriose, histeromioma, metrofibroma, puberdade precoce, dismenorréia, ou câncer do seio, ou um contraceptivo, e, composto
BR9906287A (pt) Bactéria pertencente ao gênero escherichia e que tem uma capacidade para produzir um l-aminoácido, e, processo para produzir um l-aminoácido
YU83502A (sh) Nova farmaceutska smeša
BR0107643A (pt) Composições e processos para a terapia e diagnóstico de c ncer de próstata
BG102969A (en) Pharmaceutical composition having continuous release of medicamentous forms capsulated in hyluronic acid microparticles
ES2189768T3 (es) Sintesis regioselectiva de derivados de rapamicina.
BR9812122A (pt) Combinação de inibidor da tirosina quinase e castração quìmica para tratar câncer da próstata
DE69734605D1 (de) Abgeschwächter salmonellenstamm, gebraucht als vehikel zur oralen immunisierung
BRPI0309769B8 (pt) composição lubrificante substancialmente anidra
DK0696921T3 (da) Veterinært præparat indeholdende en protonpumpeinhibitor
GR3030437T3 (en) Water-soluble nimesulide salt, and uses thereof for the treatment of inflammations
HRP20020198B1 (en) Moxifloxacin formulation containing common salt
BR9811094A (pt) Agente terapêutico para tumores linfáticos
IT1247945B (it) Agente avente attivita' batteriostatica e battericida
ATE355288T1 (de) Verbindungen und therapeutische methoden
PT1098643E (pt) Fenilacetilglutamina fenilacetilisoglutamina e/ou fenilacetato para o tratamento de doencas neoplasicas
ES2032955T3 (es) Sal sodica anhidra cristalina de 5-cloro-3-(2-tenoil)-2-oxindol-1-carboxamida.
BR0009472A (pt) Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas
BR0201524A (pt) Tratamento de combinação para ansiedade e depressão
ES2180729T3 (es) Tratamiento terapeutico combinado de las patologias hiperproliferantes.
DE60142899D1 (de) Verbindungen für den transfer von oligonukleotiden
PT871467E (pt) Formulacao para a libertacao de peptido
BR0111024A (pt) Composições e métodos para a terapia e diagnóstico de câncer de mama
AP2000001937A0 (en) Method for identifying chemical active agents and active agents for inhibiting the 1-desoxy-d-xylulose-5-phosphate biosynthetic pathway.
SE0100684D0 (sv) New subject-matter

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP)

Free format text: ALTERADO DE: TAKEDA CHEMICAL INDUSTRIES, LTD.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A, 9A E 10A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1990 DE 25/02/2009.